Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD)

P. Kopinski, J. Chorostowska-Wynimko, A. Dyczek, T. Iwaniec, A. Rozy, P. Jagus, K. Szablowska, T. Wandtke, B. Balicka-Slusarczyk (Bydgoszcz, Warszawa, Krakow, Poland)

Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Session: Idiopathic pulmonary fibrosis
Session type: Poster Discussion
Number: 3149
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Kopinski, J. Chorostowska-Wynimko, A. Dyczek, T. Iwaniec, A. Rozy, P. Jagus, K. Szablowska, T. Wandtke, B. Balicka-Slusarczyk (Bydgoszcz, Warszawa, Krakow, Poland). Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD). Eur Respir J 2012; 40: Suppl. 56, 3149

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF)
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009

The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF)
Source: Eur Respir J 2004; 24: Suppl. 48, 553s
Year: 2004

Erythropoietin (EPO) attenuates the immunohistochemical expression of tumor growth factor-ß (TGF-ß) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats
Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Year: 2018

Expression of insulin-growth factor-I (IGF-I) in alveolar lymphocytes (AL) in interstitial lung diseases (ILD). Potential functions of AL-derived IGF
Source: Annual Congress 2005 - Progresses in lung fibrosis
Year: 2005


Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008


Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients
Source: Eur Respir J 2003; 22: Suppl. 45, 173s
Year: 2003

Antifibrotic role of hepatocyte growth factor (HGF) in fibrosing interstial lung diseases
Source: Eur Respir J 2001; 18: Suppl. 33, 367s
Year: 2001

The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis.
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018



Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs)
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011


Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007

Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008

Epidermal growth factor receptor (EGFR) activation is required for TGFbeta1-induced epithelial-mesenchymal transition (EMT) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013

Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012

Expression of epidermal growth factor receptor (EGFR) in the bronchial epithelium of patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011

Insulin-like growth factor I (IGF-I) and binding proteins (BP-2,3,4,6) expression during the progression of idiopathic fibrosing alveolitis (IFA) and sarcoidosis
Source: Eur Respir J 2001; 18: Suppl. 33, 160s
Year: 2001

The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Haemophilus influenzae (NTHi) up-regulates acute inflammation in human lung tissue and causes downregulation of transforming growth factor-beta (TGF-beta) – A possible role of NTHi in remodeling processes in human lung tissue
Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease
Year: 2010

TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001

Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007